Suramin-induced neuropathy in an animal model

James W. Russell, Jagjit S. Gill, Eric James Sorenson, Debra A. Schultz, Anthony John Windebank

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Suramin is being used either alone, or in combination with other chemotherapeutic agents, in the treatment of hormone-refractory or metastatic prostate cancer. Use of this potentially valuable chemotherapy is limited by a dose-dependent polyneuropathy. It has been difficult in human studies to characterize peripheral suramin toxicity separately from cancer-related neuropathy. To characterize suramin-induced neuropathy in a rat model, adult rats were given either a single dose of 500 mg/kg (high dose) or 50 mg/kg (low dose) weekly suramin for 2 months. Electrophysiology and peroneal/sural nerve morphometry were performed. In high dose animals, neuropathy developed within 2 weeks, most severe in the digital sensory responses (DSR) (p<0.05) and tail and hind limb compound muscle action potential (p<0.001). Histologically, there was evidence of axonal degeneration and axon atrophy. With low dose suramin, the DSR (p<0.05) and tail distal sensory and motor responses (p<0.01) were most severely affected at 2 months. Axonal degeneration was seen in teased fibers from most animals. With TEM, there were abundant characteristic lysosomal inclusion bodies in DRG and Schwann cells. Electrophysiological and histological evidence of peripheral demyelination was rare, being observed in only one animal. Suramin induced a length, dose and time-dependent axonal sensorimotor polyneuropathy associated with axonal degeneration, atrophy, and accumulation of glycolipid lysosomal inclusions.

Original languageEnglish (US)
Pages (from-to)71-80
Number of pages10
JournalJournal of the Neurological Sciences
Volume192
Issue number1-2
DOIs
StatePublished - Nov 15 2001

Fingerprint

Suramin
Animal Models
Polyneuropathies
Atrophy
Tail
Sural Nerve
Peroneal Nerve
Electrophysiology
Diagnosis-Related Groups
Schwann Cells
Glycolipids
Inclusion Bodies
Demyelinating Diseases
Action Potentials
Axons
Prostatic Neoplasms
Extremities
Hormones
Drug Therapy
Muscles

Keywords

  • Axons
  • Demyelination
  • Neuropathy
  • Sodium suramin
  • Sphingolipids

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

Suramin-induced neuropathy in an animal model. / Russell, James W.; Gill, Jagjit S.; Sorenson, Eric James; Schultz, Debra A.; Windebank, Anthony John.

In: Journal of the Neurological Sciences, Vol. 192, No. 1-2, 15.11.2001, p. 71-80.

Research output: Contribution to journalArticle

Russell, James W. ; Gill, Jagjit S. ; Sorenson, Eric James ; Schultz, Debra A. ; Windebank, Anthony John. / Suramin-induced neuropathy in an animal model. In: Journal of the Neurological Sciences. 2001 ; Vol. 192, No. 1-2. pp. 71-80.
@article{18b1bbe5650845c1bca63e82663662b6,
title = "Suramin-induced neuropathy in an animal model",
abstract = "Suramin is being used either alone, or in combination with other chemotherapeutic agents, in the treatment of hormone-refractory or metastatic prostate cancer. Use of this potentially valuable chemotherapy is limited by a dose-dependent polyneuropathy. It has been difficult in human studies to characterize peripheral suramin toxicity separately from cancer-related neuropathy. To characterize suramin-induced neuropathy in a rat model, adult rats were given either a single dose of 500 mg/kg (high dose) or 50 mg/kg (low dose) weekly suramin for 2 months. Electrophysiology and peroneal/sural nerve morphometry were performed. In high dose animals, neuropathy developed within 2 weeks, most severe in the digital sensory responses (DSR) (p<0.05) and tail and hind limb compound muscle action potential (p<0.001). Histologically, there was evidence of axonal degeneration and axon atrophy. With low dose suramin, the DSR (p<0.05) and tail distal sensory and motor responses (p<0.01) were most severely affected at 2 months. Axonal degeneration was seen in teased fibers from most animals. With TEM, there were abundant characteristic lysosomal inclusion bodies in DRG and Schwann cells. Electrophysiological and histological evidence of peripheral demyelination was rare, being observed in only one animal. Suramin induced a length, dose and time-dependent axonal sensorimotor polyneuropathy associated with axonal degeneration, atrophy, and accumulation of glycolipid lysosomal inclusions.",
keywords = "Axons, Demyelination, Neuropathy, Sodium suramin, Sphingolipids",
author = "Russell, {James W.} and Gill, {Jagjit S.} and Sorenson, {Eric James} and Schultz, {Debra A.} and Windebank, {Anthony John}",
year = "2001",
month = "11",
day = "15",
doi = "10.1016/S0022-510X(01)00633-5",
language = "English (US)",
volume = "192",
pages = "71--80",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Suramin-induced neuropathy in an animal model

AU - Russell, James W.

AU - Gill, Jagjit S.

AU - Sorenson, Eric James

AU - Schultz, Debra A.

AU - Windebank, Anthony John

PY - 2001/11/15

Y1 - 2001/11/15

N2 - Suramin is being used either alone, or in combination with other chemotherapeutic agents, in the treatment of hormone-refractory or metastatic prostate cancer. Use of this potentially valuable chemotherapy is limited by a dose-dependent polyneuropathy. It has been difficult in human studies to characterize peripheral suramin toxicity separately from cancer-related neuropathy. To characterize suramin-induced neuropathy in a rat model, adult rats were given either a single dose of 500 mg/kg (high dose) or 50 mg/kg (low dose) weekly suramin for 2 months. Electrophysiology and peroneal/sural nerve morphometry were performed. In high dose animals, neuropathy developed within 2 weeks, most severe in the digital sensory responses (DSR) (p<0.05) and tail and hind limb compound muscle action potential (p<0.001). Histologically, there was evidence of axonal degeneration and axon atrophy. With low dose suramin, the DSR (p<0.05) and tail distal sensory and motor responses (p<0.01) were most severely affected at 2 months. Axonal degeneration was seen in teased fibers from most animals. With TEM, there were abundant characteristic lysosomal inclusion bodies in DRG and Schwann cells. Electrophysiological and histological evidence of peripheral demyelination was rare, being observed in only one animal. Suramin induced a length, dose and time-dependent axonal sensorimotor polyneuropathy associated with axonal degeneration, atrophy, and accumulation of glycolipid lysosomal inclusions.

AB - Suramin is being used either alone, or in combination with other chemotherapeutic agents, in the treatment of hormone-refractory or metastatic prostate cancer. Use of this potentially valuable chemotherapy is limited by a dose-dependent polyneuropathy. It has been difficult in human studies to characterize peripheral suramin toxicity separately from cancer-related neuropathy. To characterize suramin-induced neuropathy in a rat model, adult rats were given either a single dose of 500 mg/kg (high dose) or 50 mg/kg (low dose) weekly suramin for 2 months. Electrophysiology and peroneal/sural nerve morphometry were performed. In high dose animals, neuropathy developed within 2 weeks, most severe in the digital sensory responses (DSR) (p<0.05) and tail and hind limb compound muscle action potential (p<0.001). Histologically, there was evidence of axonal degeneration and axon atrophy. With low dose suramin, the DSR (p<0.05) and tail distal sensory and motor responses (p<0.01) were most severely affected at 2 months. Axonal degeneration was seen in teased fibers from most animals. With TEM, there were abundant characteristic lysosomal inclusion bodies in DRG and Schwann cells. Electrophysiological and histological evidence of peripheral demyelination was rare, being observed in only one animal. Suramin induced a length, dose and time-dependent axonal sensorimotor polyneuropathy associated with axonal degeneration, atrophy, and accumulation of glycolipid lysosomal inclusions.

KW - Axons

KW - Demyelination

KW - Neuropathy

KW - Sodium suramin

KW - Sphingolipids

UR - http://www.scopus.com/inward/record.url?scp=0035889614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035889614&partnerID=8YFLogxK

U2 - 10.1016/S0022-510X(01)00633-5

DO - 10.1016/S0022-510X(01)00633-5

M3 - Article

C2 - 11701155

AN - SCOPUS:0035889614

VL - 192

SP - 71

EP - 80

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -